Skip Navigation



NDT Advance Access published online on September 19, 2009
Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfp488
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Haynes, R. J.
Right arrow Articles by Winearls, C. G.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Haynes, R. J.
Right arrow Articles by Winearls, C. G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press [on behalf of ERA-EDTA]. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org


Presentation and survival of patients with severe acute kidney injury and multiple myeloma: 20-year experience from a single centre

Richard J. Haynes1,2, Simon Read2, Graham P. Collins3, Sarah C. Darby2 and Christopher G. Winearls1

1 Oxford Kidney Unit, Churchill Hospital 2 Clinical Trial Service Unit & Epidemiological Studies Unit, University of Oxford 3 Department of Haematology, Oxford Radcliffe Hospital, Oxford, UK

Correspondence and offprint requests to: Richard Haynes; E-mail: richard.haynes{at}ctsu.ox.ac.uk



  Abstract

Background. Myeloma is the second most common haematological malignancy and is a cause of severe acute kidney injury (serum creatinine ≥500 µmol/L) that has long been associated with a poor prognosis, although previous series have been small.

Methods. We have therefore documented the natural history of all 107 patients referred to a large regional renal unit over a 20-year period and investigated factors associated with survival over a long period of time using Cox regression methods.

Results. Three factors were found to be significantly and independently associated with survival: use of chemotherapy [hazard ratio (HR) 0.21, 95% CI: 0.08–0.46, P < 0.001], serum albumin (HR 0.49, 95% CI: 0.29–0.82, P = 0.02 for ≥35 g/L versus <35 g/L) and dialysis independence (HR 0.43, 95% CI: 0.24–0.76, P = 0.005). However, survival was not found to be better for patients presenting in the second decade compared to the first (HR 0.88, 95% CI: 0.52–1.50, P = 0.65).

Conclusions. This analysis highlights the need for clinical trials of novel chemotherapy regimens in this complicated group of patients. Furthermore, whether strategies to restore or preserve dialysis-independent renal function provide additional benefit to effective chemotherapy also requires further investigation. The advent of efficacious low toxicity chemotherapy (such as thalidomide and bortezomib) and new dialysis techniques to remove free light chains may radically alter the outcome of this group of patients.

Keywords: acute kidney injury; clinical epidemiology; multiple myeloma; prognosis; survival analysis

Received for publication: 16. 1.09
Accepted in revised form: 21. 8.09


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.